Screener
Gilead Sciences GILD Royalty, contract and other revenues — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions, except per share amounts) | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Product sales | $7,627 | $7,054 | $14,574 | $13,668 |
| Royalty, contract and other revenues | 176 | 27 | 189 | 81 |
| Total revenues | 7,803 | 7,082 | 14,763 | 13,749 |
| Costs and expenses: | ||||
| Cost of goods sold | 1,579 | 1,501 | 3,023 | 3,041 |
| Research and development expenses | 1,764 | 1,491 | 3,136 | 2,870 |
| Acquired in-process research and development expenses | 11,183 | 61 | 11,290 | 315 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's royalty, contract and other revenues — total revenues?
- Gilead Sciences (GILD) reported royalty, contract and other revenues — total revenues of $176M in Q2 2026.
- How has Gilead Sciences's royalty, contract and other revenues — total revenues changed year-over-year?
- Gilead Sciences's royalty, contract and other revenues — total revenues increased by 551.9% year-over-year, from $27M to $176M.
- What is the long-term trend for Gilead Sciences's royalty, contract and other revenues — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's royalty, contract and other revenues — total revenues has grown at a 15.4% compound annual growth rate (CAGR), from $297M to $527M.
- What does royalty, contract and other revenues — total revenues mean?
- This metric represents the total revenue generated from licensing intellectual property, contractual arrangements, and ancillary business activities outside of direct product sales. It captures income streams derived from royalties on third-party sales of licensed technologies and payments from collaborative research or development agreements. This revenue source reflects the company's ability to monetize its patent portfolio and strategic partnerships without incurring the direct costs associated with manufacturing or distributing commercial products.
Ask your AI about Gilead Sciences's royalty, contract and other revenues — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude